A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.

Aspergillosis, Azole resistance, Treatment
dx.doi.org/10.1111/myc.12440, hdl.handle.net/1765/91210
Department of Medical Microbiology and Infectious Diseases

Lestrade, P.P.A, Meis, J.F, Arends, J.P.A, van der Beek, M.T, de Brauwer, E.I.G.B, van Dijk, K, … Verweij, P.E. (2016). Diagnosis and management of aspergillosis in the Netherlands: A national survey. Mycoses, 59(2), 101–107. doi:10.1111/myc.12440